This edition features updates from: The EU and Unified Patent Court (UPC).
The Irides Weekly Update is our round-up of patent litigation news highlights from around the world.
.png)
EU
European Parliament briefing suggests reforms to the Intellectual Property Rights Enforcement Directive.
A September 2026 European Parliament briefing has called for reform of the Intellectual Property Rights Enforcement Directive (IPRED) to ensure greater proportionality in the application of patent remedies. It cites the importance of considering tailored relief in the context of permanent injunctions and corrective measures (such as recall and destruction of goods).
The briefing considers that permanent injunctions may be particularly problematic in the context of complex products (where infringement of a patent reading on a minor component of a complex product could affect manufacturing and sales of the whole product) and when used by non-practising entities. It proposes clearer statutory factors for assessing injunctions. Rather than denying injunctions entirely, it favours tailored remedies, including delayed injunctions, stays and sell-off periods, while compensating patent holders through appropriate royalties.
The briefing also notes that national courts have been more wary, as compared to the CJEU, in applying principles of proportionality. The Unified Patent Court is particularly called out for its reluctance to consider proportionality in the context of injunctions, particularly outside cases involving patient interests.
.png)
UPC
Milan Local Division breaks new ground with successful FRAND defence for ASUS.
[Ericsson v ASUS UPC_CFI_318/2024, UPC_CFI_730/2024]
On 6 November 2026, the Milan Local Division handed down its decision in proceedings brought by Telefonaktiebolaget LM Ericsson (Ericsson) against ASUSTeK Computer Inc. (ASUSTeK) and Arvato Netherlands B.V. (Arvato), a Dutch logistics provider.
ASUSTeK raised a FRAND defence based on Art. 102 TFEU. The Court applied the framework set out by the CJEU in Huawei v ZTE, which requires a dominant SEP holder, before bringing an action for an injunction, to notify the alleged infringer by identifying the patent and specifying how it was infringed. The Court held that the Huawei v ZTE steps had to be followed in chronological sequence. Ericsson had identified EP 342 and the alleged infringement only on 14 June 2024, the same day it lodged its Statement of Claim. The Court held that notice given upon or after the commencement of proceedings could not cure the failure to give notice beforehand. Neither the public availability of ITU registers nor Ericsson’s request for an injunction conditional on ASUSTeK accepting a licence was an adequate substitute. ASUSTeK’s FRAND defence therefore succeeded.
The Court held that a well-founded FRAND defence did not preclude all of the remedies sought by an SEP holder. It precluded an injunction and the recall and destruction of products, but not a declaration of infringement, a finding of liability for damages or an order to provide information. The Court declared ASUSTeK liable for damages in principle, reserving the amount and the relevant period for subsequent proceedings.
.png)
UPC
Düsseldorf Local Division sets a high bar for prior public use and novelty challenges.
[Dai Nippon Printing v Zapp UPC_CFI_466/2025, UPC_CFI_869/2025]
On 5 November 2026, in Dai Nippon Printing v Zapp, the Düsseldorf Local Division (LD) gave useful guidance on the evidence required to establish prior public use. The LD held that a party relying on prior public use must establish, without gaps, what was made available, when, to whom and in what circumstances. Where testing is relied on to establish the properties of products supplied before the priority date, the samples tested must also be reliably linked to the products actually supplied. The LD found EP 3 805 415, concerning metal plates used to manufacture deposition masks, valid and infringed; and dismissed Zapp’s counterclaim for revocation.
Zapp’s prior public use case failed because it had not established the identity of the samples tested with sufficient certainty. The LD identified deficiencies in the sampling documentation and inconsistencies concerning the samples, together with issues as to the reliability of the testing. It was therefore not established that products possessing all the features of the claimed invention had been made available to the public before the priority date.
On novelty, the LD held that prior art must be considered as a whole and cannot be treated as a “reservoir” from which individual features can be selected to construct a novelty destroying embodiment. Different passages may only be combined where there is a clear and unambiguous teaching to do so. The LD also held that disclosure of a broader numerical range does not automatically anticipate a narrower claimed range falling within it, particularly where several parameters must be satisfied cumulatively and the prior art does not address all of the claimed ranges.
.png)
UPC
GSK secures cross-border injunction over Comirnaty.
[GSK v Pfizer & BioNTech UPC_CFI_620/2025, UPC_CFI_1509/2025, UPC_CFI_1511/2025]
On 10 November 2026, The Hague Local Division (LD) issued its decision in GSK v Pfizer and BioNTech. The decision contains commentary on a number of “hot topics” before the UPC, including its long-arm jurisdiction, the construction of claims containing numerical limits, the application of partial priority, the assessment of novelty and combining features from a prior art document, defining the CGK and joint infringement. The LD held GSK’s patent on liposomes for RNA vaccine delivery valid, with the exception of claim 13, and infringed by Pfizer and BioNTech’s Comirnaty (SARS-CoV-2) vaccines.
For the defendants domiciled in the UPC territory, the LD found that jurisdiction based on domicile is universal and extends to alleged infringement of the national parts of the patent in other EPC countries. For defendants outside the UPC territory, Art. 8(1) Brussels Recast, or where relevant the equivalent Art. 6(1) Lugano Convention, provided jurisdiction because there was a sufficient connection with the claims against anchor defendants responsible for the manufacture and marketing of Comirnaty. The result was jurisdiction over alleged infringement in all EPC countries where the patent was valid, except Ireland and the UK, as requested by GSK.
On construction and infringement, the LD rejected Pfizer and BioNTech’s argument that the ends of the specified lipid pKa range “5.0 to 6.8” were absolute cut-offs. It was held that the skilled person would understand, including based on documents incorporated by reference, that measurements made using that method were precise only to about 0.2 units. This finding proved material to technical infringement, as the pKa measurements of the ALC-0315 lipid in Comirnaty submitted by GSK in a testing report were consequently held to fall within the claimed range.
Having found the patent application entitled to claim partial priority, applying the Enlarged Board’s decision in G 1/15, the LD considered the novelty and obviousness attacks. The decision provides useful guidance on the prohibition against treating a prior art document as a reservoir from which features may be freely selected for novelty purposes. The question is whether the skilled person would understand the particular combination to be disclosed as part of the document’s technical teaching. On the facts, selecting an ionisable cationic lipid from a list in one claim and combining it with features in other claims of the prior art patent amounted to impermissible mosaicking, particularly where the document provided no reason to make that selection.
The Court took a relatively demanding approach to establishing CGK. In its view, CGK is concerned primarily with whether particular knowledge, rather than a particular document, was common and generally accepted. The real question is whether the factual proposition is sufficiently elementary, convincing and consensual that the skilled person would necessarily know it and the relevant technical community would have accepted it as an established empirical fact.
On infringement, a point of broad significance was the attribution of infringing acts across corporate groups. The LD considered the Pfizer and BioNTech groups to operate through integrated and centrally controlled operational structures in relation to the manufacture and commercialisation of Comirnaty, such that they performed or contributed as joint infringers. It rejected the proposition that the precise type of infringing act needed to be established separately against every defendant. Given the integrated supply and distribution structure, the LD found the infringing acts jointly attributable to the defendants, even though the precise contribution of each entity in each jurisdiction could not be distinguished.
The LD went on to grant an injunction extending to all EPC countries where the patent was valid, except Ireland and the UK, and its approach to enforceability is notable. The injunction will not become enforceable until the UPC decision is final and irrevocable and, even then, only if Pfizer and BioNTech have not entered into a licence with GSK within a further three months. In reaching that result, the LD emphasised proportionality. Postponing enforceability struck the balance between the parties’ interests: it avoided requiring withdrawal of Comirnaty while an appeal is pending and provided a further opportunity to agree a licence if the infringement finding becomes final.
.png)
New episodes: You, Me and the UPC: Case by case
Episode 103: The Munich LD considers whether damages can extend beyond the infringing product.
Episode 104: Court of Appeal clarifies public prior use test in partial revocation of Agfa patent.

/Passle/5f3d6e345354880e28b1fb63/MediaLibrary/Images/2025-09-29-13-48-10-128-68da8e1af6347a2c4b96de4e.png)
/Passle/5f3d6e345354880e28b1fb63/SearchServiceImages/2026-11-12-17-32-40-845-6af5f8381d08c17997a20ca9.jpg)
/Passle/5f3d6e345354880e28b1fb63/MediaLibrary/Images/2024-08-01-13-11-10-549-66ab896ee543bf94f9636c73.png)
/Passle/5f3d6e345354880e28b1fb63/SearchServiceImages/2026-11-13-17-21-43-728-6af74727aa2f737717156ee5.jpg)